Literature DB >> 16645504

T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis.

Virginia Amanatidou1, George Sourvinos, Stavros Apostolakis, Amalia Tsilimigaki, Demetrios A Spandidos.   

Abstract

BACKGROUND: Recent data suggest that immunologic response during respiratory syncytial virus (RSV) infection is partially modified through interaction of viral G glycoprotein with the host's chemokine receptor, CX3CR1. We hypothesized that two nonsynonymous, single-nucleotide polymorphisms of the CX3CR1 gene (CX3CR1-V249I and CX3CR1-T280M) that disrupt the affinity of CX3CR1 for its natural ligand (fractalkine) could also affect the G glycoprotein-CX3CR1 pathway.
METHODS: To test the hypothesis, DNA samples were obtained from 82 children hospitalized for RSV bronchiolitis in a 1-year period. One hundred twenty sex-matched healthy adults, without a history of severe lower respiratory tract infections, formed the control group.
RESULTS: Epidemiologic data showed an increase in the RSV infection rate during the late winter season, with a peak rate in early spring. Genotyping revealed predominance of the 280M-containing genotypes (M/M or T/M) in cases compared with controls (37.8% versus 20.8%, respectively; odds ratio, 2.03; 95% confidence interval, 1.1-3.9; P = 0.025), demonstrating an association between the common CX3CR1-T280M variations and increased risk of severe RSV bronchiolitis.
CONCLUSIONS: Our findings support the hypothesis of the pivotal role of the G glycoprotein CX3CR1 pathway in the pathogenesis of RSV bronchiolitis and propose CX3CR1 as a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645504     DOI: 10.1097/01.inf.0000214998.16248.b7

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  24 in total

1.  Exploring the origins of asthma: Lessons from twin studies.

Authors:  Simon Francis Thomsen
Journal:  Eur Clin Respir J       Date:  2014-09-01

Review 2.  Therapeutic targeting of respiratory syncytial virus G-protein.

Authors:  Lawrence M Kauvar; Jennifer L Harcourt; Lia M Haynes; Ralph A Tripp
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Vitamin D-binding protein haplotype is associated with hospitalization for RSV bronchiolitis.

Authors:  A G Randolph; W-K Yip; K Falkenstein-Hagander; S T Weiss; R Janssen; S Keisling; L Bont
Journal:  Clin Exp Allergy       Date:  2014-02       Impact factor: 5.018

5.  Respiratory syncytial virus infection of newborn CX3CR1-deficient mice induces a pathogenic pulmonary innate immune response.

Authors:  Sudipta Das; Mahesh Raundhal; Jie Chen; Timothy B Oriss; Rachael Huff; John V Williams; Anuradha Ray; Prabir Ray
Journal:  JCI Insight       Date:  2017-09-07

6.  Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

Authors:  Junyan Han; Katsuyuki Takeda; Meiqin Wang; Wanjiang Zeng; Yi Jia; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2014-07       Impact factor: 6.914

Review 7.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

Review 9.  Development of asthma is determined by the age-dependent host response to respiratory virus infection: therapeutic implications.

Authors:  Erwin W Gelfand
Journal:  Curr Opin Immunol       Date:  2012-09-13       Impact factor: 7.486

10.  Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand.

Authors:  K Grimwood; C Cohet; F J Rich; S Cheng; C Wood; N Redshaw; C W Cunningham; N Pearce; J R Kirman
Journal:  Epidemiol Infect       Date:  2008-01-04       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.